Geron (NASDAQ:GERN) Announces Quarterly Earnings Results

Geron (NASDAQ:GERN) announced its quarterly earnings results on Wednesday. This biopharmaceutical company reported earnings per share of ($0.04), matching analysts' consensus expectation of ($0.04), according to Zacks. Additionally, Geron recorded a negative return on equity of 67.53% and a negative net margin of 682.48%.

Geron Stock Performance

The stock of Geron Corporation experienced a decline, trading down $0.75 during midday trading, which brought the stock price to $1.63. A total of 72,719,004 shares exchanged hands, significantly higher than the average trading volume of 13,690,789. Geron's market capitalization is approximately $982.31 million, with a price-to-earnings ratio of -5.11 and a beta of 0.53. Over the last 50 days, the simple moving average for the stock is $3.05, while the 200-day simple moving average is $3.83. Geron has seen a low of $1.46 and a high of $5.34 over the past twelve months. The company maintains a quick ratio of 2.74 and a current ratio of 2.89, with a minimal debt-to-equity ratio of 0.04.

Wall Street Analyst Opinions

Geron has drawn attention from various analysts recently. Barclays upgraded Geron to a "strong-buy" rating in a report published on November 29, while Needham & Company raised their target price for the stock from $6.00 to $7.00, also issuing a "buy" rating on January 13. Conversely, B. Riley lowered their price target from $5.50 to $3.50 while keeping a "buy" rating on Geron on February 18. Additionally, HC Wainwright adjusted their rating from "buy" to "neutral" in a report released on Wednesday. Among analysts, one has rated Geron with a sell, two with a hold, eight with a buy, and two with a strong buy rating. According to MarketBeat.com, Geron currently has an average rating of "Moderate Buy" with an average price target set at $6.91.

About Geron

Geron Corporation is a late-stage clinical biopharmaceutical organization primarily focused on developing and commercializing treatments for myeloid hematologic malignancies. The company is advancing imetelstat, a telomerase inhibitor currently in Phase 3 clinical trials. This treatment aims to inhibit the uncontrolled growth of malignant stem and progenitor cells in patients with low or intermediate-1 risk myelodysplastic syndromes, as well as intermediate-2 or high-risk myelofibrosis.

Summary

Investors may consider the mixed signals from analysts regarding Geron stock, as the company continues to navigate its clinical trials and market performance.

Earnings, Biopharmaceutical, Stocks